Rezolute (NASDAQ:RZLT – Get Free Report) had its price objective dropped by analysts at JMP Securities from $8.00 to $7.00 in a research note issued on Tuesday, Benzinga reports. The brokerage currently has a “market outperform” rating on the stock.
Several other brokerages have also recently weighed in on RZLT. Cantor Fitzgerald restated an “overweight” rating and set a $5.00 target price on shares of Rezolute in a report on Tuesday, September 19th. HC Wainwright restated a “buy” rating and issued a $14.00 target price on shares of Rezolute in a report on Monday, September 18th.
Rezolute Price Performance
Rezolute (NASDAQ:RZLT – Get Free Report) last posted its earnings results on Thursday, September 14th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.11. As a group, equities research analysts expect that Rezolute will post -1.17 earnings per share for the current year.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the company. Millennium Management LLC purchased a new stake in shares of Rezolute during the 4th quarter worth $32,000. FMR LLC purchased a new stake in Rezolute during the first quarter worth about $39,000. Renaissance Technologies LLC acquired a new position in Rezolute during the second quarter worth about $58,000. Charles Schwab Investment Management Inc. purchased a new position in Rezolute in the fourth quarter valued at about $67,000. Finally, State Street Corp acquired a new stake in shares of Rezolute during the 1st quarter valued at approximately $69,000. Institutional investors and hedge funds own 65.79% of the company’s stock.
Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.
- Five stocks we like better than Rezolute
- What Are the FAANG Stocks and Are They Good Investments?
- 3 value stocks you shouldn’t let go of this quarter
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- 5 must-have next-gen technologies that institutions are buying
- What is the Australian Securities Exchange (ASX)
- 3 intriguing late-week earnings plays for short-term traders
Receive News & Ratings for Rezolute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rezolute and related companies with MarketBeat.com's FREE daily email newsletter.